---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-026097"
form_type: "8-K"
ticker: "VIVS"
cik: "0001497253"
company_name: "VivoSim Labs, INC."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:43:52.380132+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Organovo sells FXR program to Eli Lilly for $10M upfront; faces Nasdaq delisting

## Summary
- Lilly to buy Organovo's FXR program for $10M upfront ($9M at close, $1M escrow) + up to $50M in milestones.
- Lead asset FXR314, an oral FXR agonist for IBD, to be advanced to Phase 2 by Lilly.
- Organovo faces Nasdaq delisting: stockholders' equity of $364K as of Dec 31, 2024, below $2.5M minimum.
- Hearing before Nasdaq panel scheduled Feb 27, 2025; company may pursue reverse stock split to regain bid price compliance.

## SEC filing metadata
- accession: 0000950170-25-026097
- form_type: 8-K
- ticker: VIVS
- cik: 0001497253
- company_name: VivoSim Labs, INC.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1497253/000095017025026097/0000950170-25-026097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1497253/000095017025026097/onvo-20250219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-026097
- JSON: https://secwatch.observer/filing/0000950170-25-026097.json
- Plain text: https://secwatch.observer/filing/0000950170-25-026097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.